V09-04 the Use of Spacer in Focal Cryotherapy for Rectal Protection

You have accessJournal of UrologyProstate Oncology/Penile & Testis Oncology/Misc. Oncology I (V09)1 May 2024V09-04 THE USE OF SPACER IN FOCAL CRYOTHERAPY FOR RECTAL PROTECTION Chi Hang Yee, Peter Ka-Fung Chiu, Rossella Nicoletti, Ho Fai Wong, Jeremy Yuen-Chun Teoh, Mandy Ho-Man Tam, Yun-Sang Chan, Chi-Kwok Chan, Ka-Lun Lo, Wilson Hoi-Chak Chan, and Chi-Fai Ng Chi Hang YeeChi Hang Yee , Peter Ka-Fung ChiuPeter Ka-Fung Chiu , Rossella NicolettiRossella Nicoletti , Ho Fai WongHo Fai Wong , Jeremy Yuen-Chun TeohJeremy Yuen-Chun Teoh , Mandy Ho-Man TamMandy Ho-Man Tam , Yun-Sang ChanYun-Sang Chan , Chi-Kwok ChanChi-Kwok Chan , Ka-Lun LoKa-Lun Lo , Wilson Hoi-Chak ChanWilson Hoi-Chak Chan , and Chi-Fai NgChi-Fai Ng View All Author Informationhttps://doi.org/10.1097/01.JU.0001009528.33572.9e.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Getting an adequate posterior margin for middle or posterior lesions has been a challenge for local cryotherapy. Ablation near the rectum creates risks of rectal injury. Injection of spacer between prostate and rectum has been an accepted way to protect the rectum during radiotherapy for prostate cancer. We aim to test the feasibility of using spacer in focal cryotherapy for middle or posterior lesions and to report the early post-operative outcome. METHODS: Consecutive prostate cancer patients with middle or posterior lesion diagnosed by transperineal prostate biopsy were recruited for focal cryotherapy with spacer injection. Injection of spacer (9 ml of Barrigel®) was done in the same session of focal cryotherapy. Spacer distribution during injection was tailor-made according to the laterality of the lesion. Koelis® fusion platform was used to visualize the spacer location after injection. Subsequently, cryotherapy needles were inserted to allow ablation zone to cover the lesion according to the fusion platform prediction model. Two freeze-thaw cycles were administered per conventional cryotherapy approach with temperature probe monitoring. Peri-operative data and early post-operative outcome were collected. RESULTS: In 2023, two prostate cancer patients with middle or posterior lesion were treated with spacer injection and subsequent cryotherapy. Both patients belonged to the intermediate-risk group. Operative time was 121 minutes and 160 minutes. Hospital stay was 1 day and catheter time was 7 days for both patients. No complications were noted after the surgery in the early post-operative period. CONCLUSIONS: Use of spacer in cryotherapy for middle or posterior lesions provides a safe option to achieve lesion ablation. Further study is needed to assess the long term outcome in this group of patients. Source of Funding: Nil © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e636 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Chi Hang Yee More articles by this author Peter Ka-Fung Chiu More articles by this author Rossella Nicoletti More articles by this author Ho Fai Wong More articles by this author Jeremy Yuen-Chun Teoh More articles by this author Mandy Ho-Man Tam More articles by this author Yun-Sang Chan More articles by this author Chi-Kwok Chan More articles by this author Ka-Lun Lo More articles by this author Wilson Hoi-Chak Chan More articles by this author Chi-Fai Ng More articles by this author Expand All Advertisement PDF downloadLoading ...